La vendita allo scoperto per Huize Holding dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Huize Holding. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Huize Holding (NASDAQ:HUIZ) Azioni, Report sulle vendite allo scoperto

Huize Holding

Huize Holding Ltd is an independent online insurance product and service platform in China. The company distributes on its platform insurance products underwritten by the insurance companies who cooperate with the company, who the company refers to as its insurer partners, and helps them reach a large number of insurance clients. The company's platform offers digitalized insurance purchase experience and services through various internet and mobile internet channels. The company generates revenues from the insurance brokerage fees paid by its insurer partners.

Huize Holding Limited - American Depositary Shares

Huize Holding Ltd

WIIM

ORGN

Origin Materials shares are trading lower after the company reported worse-than-expected Q3 financial results.

DESP

Despegar shares are trading higher after the company reported better-than-expected Q3 financial results.

DPRO

Draganfly shares are trading lower after the company reported worse-than-expected Q3 revenue results. HC Wainwright & Co. cut its price target on the stock from $7 to $5.

<p><strong>Microsoft Corp</strong>'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) latest advertising campaign, "This Is An Xbox," has quickly become a talking point, drawing mixed <a href="https://www.benzinga.com/general/gaming">reactions from fans. </a></p>
<p>The campaign doubles down on the idea that Xbox isn't confined to a single console but exists as a gaming platform accessible on phones, TVs and PCs.</p>
<p><strong>See Also: <a href="https://www.benzinga.com/general/gaming/24/11/41948549/xbox-handheld-a-few-years-out-says-microsoft-gaming-ceo-hints-at-cross-platform-games-new-acquisitions">Xbox Handheld &#8216;A Few Years Out,&#8217; Says Microsoft Gaming CEO; Hints At Cross-Platform Games, New Acquisitions</a></strong></p>
<p>The ads lean into this concept with quirky imagery, showing things like a TV, a cellphone, a bento box and even a cat box labeled as "Xbox."</p>
<h1 class="wp-block-heading"><strong>Fans Push Back on Microsoft's Strategy</strong></h1>
<p>The campaign has become a meme almost overnight, with critics voicing concerns over the decline of the Xbox console's significance. </p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">This is an Xbox. <a href="https://t.co/7l8DhCI8EX">pic.twitter.com/7l8DhCI8EX</a></p>
<p>&mdash; Jez (@JezCorden) <a href="https://twitter.com/JezCorden/status/1857277902485590260?ref_src=twsrc%5Etfw">November 15, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">THIS IS AN XBOX &#x1f923; <a href="https://t.co/u6Jg986O7f">https://t.co/u6Jg986O7f</a> <a href="https://t.co/qroMlziI9e">pic.twitter.com/qroMlziI9e</a></p>
<p>&mdash; &#x2699;&#xFE0F;The Gaming GrindHouse&#x2699;&#xFE0F; (@jez7780) <a href="https://twitter.com/jez7780/status/1857082844511658058?ref_src=twsrc%5Etfw">November 14, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>Over the past few years, Microsoft has focused less on selling hardware and more on <a href="https://www.benzinga.com/general/gaming/24/10/41318405/microsoft-to-test-cloud-gaming-for-owned-xbox-games-in-november-report">expanding its gaming ecosystem.</a></p>
<p>For core Xbox fans, this shift has been disappointing. Console exclusives are increasingly rare, and the <a href="https://www.benzinga.com/general/gaming/24/07/40081075/microsoft-reports-sharp-decline-in-xbox-hardware-sales-for-q4-but-theres-a-silver-lining">Xbox Series X and S have struggled to keep pace</a> with competitors in sales. The "box" that once defined the brand feels less central than ever.</p>
<h1 class="wp-block-heading"><strong>Phil Spencer Xbox&#8217;s New Direction</strong></h1>
<p>Xbox CEO <strong>Phil Spencer</strong> addressed these concerns in a recent interview <a href="https://www.rollingstone.com/culture/rs-gaming/xbox-console-future-cloud-ceo-phil-spencer-1235166597/">with </a>Rolling Stone. "It literally was a box when it first launched. It was the Direct X box. What it's grown into now is more accessibility. Xbox isn't just one device, Xbox is on your smart TV, Xbox is on your PC, Xbox is on your phone, and we're in the middle of that transition."</p>
<p>"Some people long for the simplicity of a single box, single platform, single game," he said. But he argued that today's gaming landscape has changed, referring to platforms like <a href="https://www.benzinga.com/topic/fortnite">Fortnite</a> and <a href="https://www.benzinga.com/general/gaming/24/10/41255828/roblox-denies-hindenburgs-accusations-of-inflating-metrics-failing-at-child-safety-calls-them-misl">Roblox.</a> "Today's largest games are bigger than any of the individual platforms."</p>
<p>&#8220;I think the thing that should really have longevity are the games, characters, and world — and the platforms should enable us to experience those games where we want to play," he added.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/11/41750999/xbox-game-pass-november-metal-slug-tactics-flight-simulator-lead-new-releases">Xbox Game Pass November: Metal Slug Tactics, Flight Simulator Lead New Releases</a></li>
</ul>
<p><em>Photo: Microsoft.</em></p>


Gaming

News

General

MSFT

Phil Spencer Responds To 'This Is An Xbox' Criticism: 'We're In The Middle Of A Transition'

GAME

GameSquare shares are trading lower after the company reported worse-than-expected Q3 revenue results.

REKR

Rekor Systems shares are trading lower after the company reported worse-than-expected Q3 financial results.

Fundamental Global shares are trading higher after the company reported a year-over-year increase in Q3 financial results.

Events

Trading Ideas

OKLO

Live On CNBC, Oklo Co-Founder And CEO Jacob DeWitte Discusses Q3 Results, Nuclear Power & Trump

Arm Holdings shares are trading lower after NVIDIA's 13F showed it had decreased its stake in the company by 13%.

<p>RBC Capital  analyst Nelson Ng   reiterates Northland Power (CSE2: NPI) with a Outperform and maintains C$28 price target.</p>


Price Target

Reiteration

Analyst Ratings

RBC Capital Reiterates Outperform on Northland Power, Maintains C$28 Price Target

GE Vernova shares are trading higher after Morgan Stanley raised the price target from $301 to $367 on the stock

<p>President-elect <strong>Donald Trump</strong>'s proposed Department of Government Efficiency (DOGE), led by <strong>Elon Musk</strong> and <strong>Vivek</strong> <strong>Ramaswamy</strong>, is raising questions about the future of U.S. defense contractors <a href="https://www.benzinga.com/news/global/24/11/41927289/trump-appoints-elon-musk-and-vivek-ramaswamy-to-lead-doge-targeting-bureaucracy-and-65-trillion-federal-spending-we-will-not-go-gently">and government IT firms. </a></p>
<p>Could the defense budget flatten—or even fall? And who stands to gain in this new sector shake up?</p>
<h3 class="wp-block-heading">DOGE Puts Defense Budget Under Pressure</h3>
<p>Trump's plan to restructure federal agencies and reduce wasteful spending through DOGE is a bold move, and its potential ripple effects are hard to ignore—especially for defense and government IT companies. </p>
<p>With the Department of Defense (DoD) being one of the largest slices of federal spending, investors are understandably focused on what's next for defense stocks in a DOGE-driven world.</p>
<p>On one hand, Trump's campaign has consistently expressed support for strengthening the U.S. military. </p>
<p>On the other, it's hard to make sweeping government cuts without touching the $877 billion defense budget, which accounts for 13% of federal spending as of 2023.</p>
<p><strong>Read Also:</strong> <strong><a href="https://www.benzinga.com/24/11/41965420/department-of-government-efficiency-led-by-elon-musk-and-vivek-ramaswamy-opens-x-account-with-username-doge">Elon Musk, Vivek Ramaswamy-Led Department Of Government Efficiency Opens Account On X</a></strong></p>
<h3 class="wp-block-heading">Defense Spending At All-Time Highs Spells Risks</h3>
<p>Historically, defense spending runs in decades-long cycles. Investment in the sector experiences periods of growth followed by downturns, and we may be nearing the peak of the current cycle, according to Goldman Sachs analyst Noah Poponak.</p>
<p> &#8220;The defense budget is at an all-time high, which creates difficult comparisons and challenging base effects,&#8221; the analyst said in a note published Friday. </p>
<h3 class="wp-block-heading"><strong>Key Risks For Defense Stocks</strong></h3>
<ol>
<li><strong>Peak Spending</strong>: The defense budget is hovering at historical highs, making future growth difficult.</li>
<li><strong>Geopolitical Shifts</strong>: If major conflicts ease, defense spending could decline.</li>
<li><strong>Government Debt</strong>: U.S. debt-to-GDP ratios are near record levels, increasing pressure to curb federal spending.</li>
</ol>
<p>Margins in the defense industry are already under pressure due to Pentagon efforts to shift risks onto contractors. Fixed pricing on long-term contracts, for example, has eroded unit economics. </p>
<p>At the same time, defense stocks – as tracked by the <strong>SPDR S&amp;P Aerospace &amp; Defense ETF</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XAR#NYSE">XAR</a>) – are trading at valuations above historical averages, leaving them vulnerable to a "de-rating" if the budget flattens or falls.</p>
<p>&#8220;It is difficult to embark on any large government spending reduction effort without touching defense, and there are potentially enough inefficiencies within the defense budget to reduce its total level without necessarily reducing military readiness or capability,&#8221; Poponak said. </p>
<p>The investment bank maintains a cautious stance on the defense sector, issuing Sell ratings for <strong>Lockheed Martin Corp. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), <strong>Northrop Grumman Corp.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>), <strong>L3Harris Technologies Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>), and <strong>Huntington Ingalls Industries Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HII#NYSE">HII</a>).</p>
<h3 class="wp-block-heading">Government IT: Winners In The Efficiency Game?</h3>
<p>While defense hardware could take a hit, government IT firms might find themselves potentially on the winning side of DOGE. </p>
<p>The sector has been outperforming traditional defense industries in revenue growth, driven by a market share shift toward advanced technologies like artificial intelligence, data analytics, and cybersecurity.</p>
<h3 class="wp-block-heading"><strong>Why IT Could Shine</strong>:</h3>
<ul>
<li><strong>Tech-Driven Efficiency</strong>: DOGE's focus on cutting waste could emphasize the adoption of technologies that streamline government operations.</li>
<li><strong>Advanced Capabilities</strong>: Firms offering cutting-edge solutions may be seen as key enablers of government efficiency.</li>
<li><strong>Resilient Demand</strong>: Even with DoD cuts, IT spending for Operations &amp; Maintenance and national security could remain strong.</li>
</ul>
<p>Goldman Sachs believes that companies like <strong>Booz Allen Hamilton Holding Corp.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) and <strong>Leidos Holdings Inc. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) are well-positioned to benefit.</p>
<p>On the flip side,<strong> SAIC Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NYSE">SAIC</a>) faces challenges due to slower growth and tougher competition, earning it a Sell rating from Goldman Sachs.</p>
<p>The bottom line is that Investors should prepare for a sector shakeup, as the creation of DOGE could mark a significant shift in federal spending priorities.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/24/11/42006982/activist-investor-nelson-peltz-says-he-was-a-matchmaker-for-elon-musk-with-donald-trump">Activist Investor Nelson Peltz Says He Was &#8216;A Matchmaker&#8217; For Elon Musk With Donald Trump</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Analyst Color

Equities

Government

Large Cap

Mid Cap

Regulations

Sector ETFs

Contracts

Politics

Economics

Tech

ETFs

LDOS

SAIC

Trump's DOGE Plan: Goldman Sachs Says Defense Stocks Face Risks, IT Firms Could Win

<p>Americans are <a href="https://www.benzinga.com/markets/equities/24/05/38901540/gen-z-is-charging-too-much-and-not-paying-bills-what-the-latest-credit-card-delinquency-data-say">racking up debt</a> and having a difficult time paying it off. </p>
<p>The 30 or more day delinquency rate for <strong>Discover Financial Services </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) ticked up slightly in October from 3.84% to 3.87%. This is slightly lower than the Riverwoods, Illinois-based company&#8217;s yearly high of 4.02% in January.</p>
<p>Rates are slightly higher at <strong>Capital One Financial Corp.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>), ending the month at 4.61%, slightly higher than September&#8217;s 4.53%.</p>
<p><strong>American Express Corp</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) is known for its wealthier consumer base. The New York, New York-based company has not yet released delinquency data for October, but its 30+ day rate stood at 1.4% in September.</p>
<p>Higher delinquency rates can lead to increased provisions for credit losses and tighter lending standards.</p>
<p><strong>Delinquency on the Rise:</strong> The Federal Bank of New York released its quarterly debt <a href="https://www.newyorkfed.org/medialibrary/interactives/householdcredit/data/pdf/HHDC_2024Q3">report</a> on Wednesday.</p>
<p>The report found that total household debt increased by $147 billion to $17.94 trillion in 2024&#8217;s third quarter. Credit card balances increased by $24 billion to $1.17 trillion, 8.1% higher than it was a year ago.</p>
<p>Credit card delinquency rates improved slightly overall, with 8.8% of balances transitioning to delinquency compared to 9.1% last quarter.</p>
<p>The percentage of credit card debt 90 or more days delinquent has risen faster than any other debt type in 2024.</p>
<p><strong>Also Read:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/government/regulations/24/11/42011035/just-before-bidens-term-ends-taiwan-semiconductor-lands-6-6-billion-in-us-funding-to-build-advanced-chip-plants">Just Before Biden&#8217;s Term Ends, Taiwan Semiconductor Lands $6.6 Billion in US Funding to Build Advanced Chip Plants</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Econ #s

Personal Finance

Credit Card Delinquencies Tick Up At Discover, Capital One: Total Household Debt Hovers Just Below $18 Trillion

<p>RBC Capital  analyst Greg Pardy   maintains Strathcona Resources (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SCR#TSX">SCR</a>) with a Sector Perform and raises the price target from C$34 to C$36.</p>


TSX:SCR

RBC Capital Maintains Sector Perform on Strathcona Resources, Raises Price Target to C$36

Disney shares are trading higher after the company announced it projects strong earnings growth especially in its ad supported streaming plans.

<p>Deep-pocketed investors have adopted a bearish approach towards Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in BIIB usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 15 extraordinary options activities for Biogen. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 26% leaning bullish and 66% bearish. Among these notable options, 2 are puts, totaling $80,703, and 13 are calls, amounting to $4,937,387.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $110.0 and $230.0 for Biogen, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In terms of liquidity and interest, the mean open interest for Biogen options trades today is 1866.8 with a total volume of 4,855.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Biogen's big money trades within a strike price range of $110.0 to $230.0 over the last 30 days.</p>
<h3>Biogen 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731688345_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$62.6</td>
<td>$57.7</td>
<td>$62.6</td>
<td>$110.00</td>
<td>$1.5M</td>
<td>8.7K</td>
<td align="right">751</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$65.6</td>
<td>$65.5</td>
<td>$65.5</td>
<td>$110.00</td>
<td>$1.0M</td>
<td>8.7K</td>
<td align="right">896</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$63.6</td>
<td>$62.5</td>
<td>$62.5</td>
<td>$110.00</td>
<td>$625.0K</td>
<td>8.7K</td>
<td align="right">100</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$63.5</td>
<td>$62.6</td>
<td>$62.6</td>
<td>$110.00</td>
<td>$375.6K</td>
<td>8.7K</td>
<td align="right">231</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$62.6</td>
<td>$57.7</td>
<td>$62.6</td>
<td>$110.00</td>
<td>$319.2K</td>
<td>8.7K</td>
<td align="right">108</td>
</tr>
</tbody>
</table>
</p>
<h3>About Biogen</h3>
<p>Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.</p>
<p>After a thorough review of the options trading surrounding Biogen, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Current Position of Biogen</h3>
<ul>
<li>Currently trading with a volume of 610,232, the BIIB's price is down by -2.38%, now at $160.97. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 88 days.</li>
</ul>
<h3>What The Experts Say On Biogen</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $219.8.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Equal-Weight rating for Biogen, targeting a price of $180.<br />
&#x2A; An analyst from Morgan Stanley has revised its rating downward to Equal-Weight, adjusting the price target to $204.<br />
&#x2A; Reflecting concerns, an analyst from Needham lowers its rating to Buy with a new price target of $270.<br />
&#x2A; An analyst from Oppenheimer persists with their Outperform rating on Biogen, maintaining a target price of $255.<br />
&#x2A; Reflecting concerns, an analyst from Citigroup lowers its rating to Neutral with a new price target of $190.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Biogen options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Markets

BIIB

Biogen Unusual Options Activity

<p>Deep-pocketed investors have adopted a bearish approach towards Synopsys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SNPS usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Synopsys. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 25% leaning bullish and 37% bearish. Among these notable options, 3 are puts, totaling $88,885, and 5 are calls, amounting to $268,163.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $520.0 to $670.0 for Synopsys during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of Synopsys stands at 140.67, with a total volume reaching 322.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Synopsys, situated within the strike price corridor from $520.0 to $670.0, throughout the last 30 days.</p>
<h3>Synopsys Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731688340_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SNPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$54.7</td>
<td>$54.5</td>
<td>$54.5</td>
<td>$600.00</td>
<td>$76.3K</td>
<td align="right">13</td>
<td align="right">18</td>
</tr>
<tr>
<td>SNPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$41.8</td>
<td>$36.7</td>
<td>$38.0</td>
<td>$520.00</td>
<td>$61.7K</td>
<td align="right">43</td>
<td align="right">0</td>
</tr>
<tr>
<td>SNPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$620.00</td>
<td>$46.2K</td>
<td align="right">367</td>
<td align="right">154</td>
</tr>
<tr>
<td>SNPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$29.3</td>
<td>$28.4</td>
<td>$28.0</td>
<td>$540.00</td>
<td>$45.7K</td>
<td align="right">105</td>
<td align="right">5</td>
</tr>
<tr>
<td>SNPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$54.5</td>
<td>$54.5</td>
<td>$54.5</td>
<td>$600.00</td>
<td>$38.1K</td>
<td align="right">13</td>
<td align="right">33</td>
</tr>
</tbody>
</table>
</p>
<h3>About Synopsys</h3>
<p>Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.</p>
<p>Having examined the options trading patterns of Synopsys, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Synopsys's Current Market Status</h3>
<ul>
<li>With a trading volume of 217,362, the price of SNPS is down by -3.59%, reaching $528.62.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 19 days from now.</li>
</ul>
<h3>Expert Opinions on Synopsys</h3>
<p>A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $658.75.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Loop Capital downgraded its action to Buy with a price target of $675.<br />
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on Synopsys with a target price of $670.<br />
&#x2A; In a cautious move, an analyst from Mizuho downgraded its rating to Outperform, setting a price target of $650.<br />
&#x2A; An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $640. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Synopsys options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


SNPS

Synopsys Unusual Options Activity

<p>Financial giants have made a conspicuous bullish move on NIO. Our analysis of options history for NIO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) revealed 9 unusual trades.</p>
<p>Delving into the details, we found 44% of traders were bullish, while 44% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $498,343, and 4 were calls, valued at $260,650.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $3.0 and $17.5 for NIO, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in NIO's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to NIO's substantial trades, within a strike price spectrum from $3.0 to $17.5 over the preceding 30 days.</p>
<h3>NIO Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731688335_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NIO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$0.97</td>
<td>$0.96</td>
<td>$0.96</td>
<td>$5.00</td>
<td>$219.3K</td>
<td>60.2K</td>
<td>4.0K</td>
</tr>
<tr>
<td>NIO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$0.98</td>
<td>$0.96</td>
<td>$0.97</td>
<td>$5.00</td>
<td>$153.3K</td>
<td>60.2K</td>
<td>1.7K</td>
</tr>
<tr>
<td>NIO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$1.41</td>
<td>$1.35</td>
<td>$1.4</td>
<td>$5.00</td>
<td>$140.0K</td>
<td>51.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>NIO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$13.05</td>
<td>$13.0</td>
<td>$13.05</td>
<td>$17.50</td>
<td>$62.6K</td>
<td>75</td>
<td>48</td>
</tr>
<tr>
<td>NIO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$1.43</td>
<td>$1.41</td>
<td>$1.43</td>
<td>$5.00</td>
<td>$42.1K</td>
<td>51.2K</td>
<td>1.3K</td>
</tr>
</tbody>
</table>
</p>
<h3>About NIO</h3>
<p>Nio is a leading electric vehicle maker, targeting the premium segment. Founded in November 2014, Nio designs, develops, jointly manufactures, and sells premium smart electric vehicles. The company differentiates itself through continuous technological breakthroughs and innovations such as battery swapping and autonomous driving technologies. Nio launched its first model, its ES8 seven-seater electric SUV, in December 2017, and began deliveries in June 2018. Its current model portfolio includes midsize to large sedans and SUVs. It sold over 160,000 EVs in 2023, accounting for about 2% of the China passenger new energy vehicle market.</p>
<p>After a thorough review of the options trading surrounding NIO, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of NIO</h3>
<ul>
<li>Trading volume stands at 19,370,337, with NIO's price down by -0.93%, positioned at $4.39.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 5 days.</li>
</ul>
<h3>What Analysts Are Saying About NIO</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $6.6.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Showing optimism, an analyst from Macquarie upgrades its rating to Outperform with a revised price target of $6. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for NIO, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


This Is What Whales Are Betting On NIO

ELAN

Elanco Acquires Speke Manufacturing Facility For $25M, Securing Critical Supply Chain For Farm Animal Products Generating $160M-$180M Annually; Expected To Impact 2025 Adjusted EBITDA By $25M-$35M

<p>RBC Capital  analyst Logan Reich   reiterates Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) with a Outperform and maintains $70 price target.</p>


RBC Capital Reiterates Outperform on Chipotle Mexican Grill, Maintains $70 Price Target

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Pre-market stock movers are a hot topic on Thursday and we have all the hottest news behind these movements!</p>



<p>Moving stocks this morning are study data, acquisition updates, a secondary stock offering and more.</p>



<p>Let&rsquo;s get into that news below!</p>



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li><strong>SMX (Security Matters)</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/smx-stock-quote/"><strong>SMX</strong></a>) stock is rocketing more than 100% alongside heavy pre-market trading.</li>



<li><strong>Tempest Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/tpst-stock-quote/"><strong>TPST</strong></a>) shares are soaring over 50% <a href="https://www.nasdaq.com/press-release/tempest-report-new-data-global-randomized-combination-study-amezalpat-tpst-1120-first">with new study data</a>.</li>



<li><strong>Reliance Global Group</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/reli-stock-quote/"><strong>RELI</strong></a>) stock is surging close to 35% on <a href="https://www.stocktitan.net/news/RELI/reliance-global-group-provides-update-on-pending-spetner-swj01901tpjv.html">an acquisition update</a>.</li>



<li><strong>Nexalin Technology</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/nxl-stock-quote/"><strong>NXL</strong></a>) shares are gaining more than 21% without any clear news this morning.</li>



<li><strong>Molecular Partners</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/moln-stock-quote/"><strong>MOLN</strong></a>) stock is rising over 17% on Thursday morning.</li>



<li><strong>Denali Capital</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/deca-stock-quote/"><strong>DECA</strong></a>) shares are increasing more than 17% in <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318402456&amp;type=PDF&amp;symbol=DECAU&amp;cdn=cb73376de3b0882ecdc7b6dd0bf51177&amp;companyName=Denali+Capital+Acquisition+Corp.+Unit&amp;formType=PRE+14A&amp;formDescription=Preliminary+proxy+statement+providing+notification+matters+to+be+brought+to+a+vote&amp;dateFiled=2024-06-18">shareholder meeting plans</a>.</li>



<li><strong>Schmid Group</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/shmd-stock-quote/"><strong>SHMD</strong></a>) stock is climbing over 16% today.</li>



<li><strong>Presto Automation</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/prst-stock-quote/"><strong>PRST</strong></a>) shares are heading more than 16% higher this morning.</li>



<li><strong>Talphera </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/tlph-stock-quote/"><strong>TLPH</strong></a>) stock is jumping over 15% without any obvious news to report.</li>



<li><strong>Aslan Pharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/asln-stock-quote/"><strong>ASLN</strong></a>) shares are up more than 14% on Thursday.</li>
</ol><h2>10 Top Losers</h2>



<ol><li><strong>Avrobio </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/avro-stock-quote/"><strong>AVRO</strong></a>) stock is crashing over 91% on <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318400833&amp;type=PDF&amp;symbol=AVRO&amp;cdn=ca84ee38e74b0f6636bad1d41ecb78df&amp;companyName=AVROBIO+Inc.&amp;formType=8-K%2FA&amp;formDescription=%5BAmend%5DCurrent+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-06-18">merger and reverse stock split news</a>.</li>



<li><strong>NLS Pharmaceutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/nlsp-stock-quote/"><strong>NLSP</strong></a>) shares are plummeting more than 22% <a href="https://investorplace.com/2024/06/why-is-nls-pharmaceutics-nlsp-stock-up-163-today/">after a recent rally</a>.</li>



<li><strong>Kaival Brands Innovations</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/kavl-stock-quote/"><strong>KAVL</strong></a>) stock is diving over 17% on Thursday.</li>



<li><strong>1847 Holdings</strong> (NYSEMKT:<a href="https://investorplace.com/stock-quotes/efsh-stock-quote/"><strong>EFSH</strong></a>) shares are taking a more than 17% beating on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318402194&amp;type=PDF&amp;symbol=EFSH&amp;cdn=8afe17ea6c0dfe97988938c03ada1ad9&amp;companyName=1847+Holdings+LLC&amp;formType=424B3&amp;formDescription=Prospectus+%5BRule+424%28b%29%283%29%5D&amp;dateFiled=2024-06-18">proposed secondary stock offering</a>.</li>



<li><strong>La Rosa</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/lrhc-stock-quote/"><strong>LRHC</strong></a>) stock is tumbling over 16% after a <a href="https://www.nasdaq.com/press-release/la-rosa-holdings-corp-announces-plans-acquire-controlling-interest-red-door-title">recent rally on acquisition news</a>.</li>



<li><strong>Huize </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/huiz-stock-quote/"><strong>HUIZ</strong></a>) shares are sliding more than 15% on <a href="https://www.nasdaq.com/press-release/huize-acquires-leading-vietnam-insurtech-platform-global-care-2024-06-20">an acquisition announcemcent</a>.</li>



<li><strong>Actelis Networks</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/asns-stock-quote/"><strong>ASNS</strong></a>) stock is falling over 13% <a href="https://investorplace.com/2024/06/why-is-actelis-networks-asns-stock-up-144-today/">after a rally</a>.</li>



<li><strong>N2OFF </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/nito-stock-quote/"><strong>NITO</strong></a>) shares are decreasing more than 13% <a href="https://www.nasdaq.com/press-release/n2off-save-foods-expanding-latin-america-new-purchase-order-peruvian-customer-2024-06">after a similar rally</a>.</li>



<li><strong>Mustang Bio</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/mbio-stock-quote/"><strong>MBIO</strong></a>) stock is dropping over 13% <a href="https://investorplace.com/2024/06/why-is-mustang-bio-mbio-stock-up-347-today/">following a rally</a>.</li>



<li><strong>Qualigen Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/qlgn-stock-quote/"><strong>QLGN</strong></a>) shares close out our pre-market stock movers down 13% today.</li>
</ol><p><em>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-june-20th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Huize Holding (HUIZ) has released an update. Huize Holding Limited, a prominent insurtech platform in China, has successfully met Nasdaq's Minimum ...

Huize Regains Nasdaq Listing Compliance

Huize Holding (HUIZ) has released an update. Huize Holding Limited has announced the replacement of its independent registered public accounting fi...

Huize Holding Appoints New Auditor Deloitte

Huize announces partnership with New China Life Insurance

Huize Holding (HUIZ) has released an update. Huize Holding Limited's Poni Insurtech has acquired a 71.7% majority stake in Vietnam's Global Care, s...

Huize Expands ASEAN Footprint with Vietnam Insurtech Acquisition

Huize Holding (HUIZ) has released an update. Huize Holding Limited, an insurance technology platform listed on Nasdaq, has received a notice from N...

Huize Holding Faces Nasdaq Minimum Bid Price Notice

Huize collaborates with New China Life Insurance for annuity product

Huize Holding reports Q2 results

Huize Holding Limited (HUIZ) Q2 2024 Earnings Call Transcript

Huize Holding (HUIZ) has released an update. Huize Holding Limited, a leading Asian insurance technology platform, reported a slight decrease in Gr...

Huize Holding Reports Mixed Q2 2024 Results

ASLN

ASNS

AVRO

DECA

EFSH

HUIZ

KAVL

LRHC

MBIO

MOLN

NITO

NLSP

PRST

QLGN

RELI

SHMD

TLPH

TPST

Press Releases

Huize Acquires Leading Vietnam Insurtech Platform Global Care

Huize Holding Limited Regains Compliance with Nasdaq Minimum Bid Price Requirement

Huize Announces Strategic Partnership with New China Life Insurance to Jointly Launch "Bliss" – A Customized Annuity Insurance Product

Huize Partners with CPIC P&C to Launch "Little Scholar" – A Customized Student Accident Insurance Product

Huize's International Arm Poni Insurtech Completes Acquisition of Controlling Stake in Global Care, a Leading Insurtech Platform in Vietnam

Huize Holding Limited to Report Second Quarter 2024 Financial Results on September 25, 2024

Huize Partners with New China Life Insurance to Launch "Bliss No.2" – A Customized Lifetime Annuity Insurance Product

Earnings

Huize Holding Limited Reports Second Quarter 2024 Unaudited Financial Results

Poni Insurtech and Global Care Launch Health Insurance Comparison Platform in Vietnam

Huize Holding Limited to Hold Annual General Meeting on November 29, 2024

Abacus Life

Arthur J. Gallagher

Aon plc Class A Ordinary Shares (Ireland)

Brown & Brown

The Baldwin Insurance Group, Inc. - Class A Common Stock

Baldwin Insurance

Cheche Group Inc. - Class A Ordinary Shares

Cheche Group

Crawford & Company Common Stock

eHealth

GoHealth

Goosehead Insurance, Inc. - Class A Common Stock

Goosehead Insurance

Hagerty

Hippo Holdings

Marsh & McLennan Companies, Inc. Common Stock

Marsh & McLennan

Ryan Specialty Holdings, Inc. Class A Common Stock

Ryan Specialty Hldgs

SelectQuote

TIAN RUIXIANG Holdings Ltd - Class A Ordinary Shares

Tian Ruixiang Holdings

TWFG

Waterdrop Inc. American Depositary Shares (each representing the right to receive 10 Class A Ordinary Shares)

Waterdrop

Willis Towers Watson Public Limited Company - Ordinary Shares

Willis Towers Watson

XChange TEC.INC - American Depositary Shares

XChange Tec

Zhibao Technology Inc. - Class A Ordinary Shares

Zhibao Technology

Comments

Huize Holding

Vendite allo scoperto

Huize Holding (NASDAQ:HUIZ) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO